Home

Pharma China Web Edition

Pharma China Archives

Online Databases

Subscription/Order/Info

Event Calendar

China Pharma Providers

About Us

	News     The Market     Industry News     Regulatory News     General Health     Legal/IPR News     Product/R&D News     API/Bulk Drug News     People in the News     Other News     Top News Worldwide Feature articles     Editorials     Commentaries     Expert Opinions     Interviews     Case Studies     Company Profiles     Editor´s Picks Full Text Title

The Market Industry News Regulatory News General Health Legal/IPR News Product/R&D News API/Bulk Drug News People in the News Other News Top News Worldwide Editorials Commentaries Expert Opinions Interviews Case Studies Company Profiles Editor´s Picks

Uncertainties Persist amid Conflicting Signals as China Intensifies Healthcare R... Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on latest market data analysis and mixed signs on the horizo... (8/1/2020) Uncertainties Persist amid Conflicting Signals as China Intensifies Healthcare Reform and Cost Containment (8/1/2020) China's Proposals to Provide a Patent Linkage System and Patent Term Extensions - Considerations for Drug Companies (7/29/2020) China: Looking Back at 2019's Main IP Developments and Looking Forward At What 2020 May Bring (7/28/2020) New Draft Patent Law - What To Expect and What Not to Expect (7/16/2020) Long Awaited Chinese Civil Code - Impacts on IPR (7/14/2020) China's Latest Patent Law Amendment Introduces Patent Linkage And Patent Term Extension (7/14/2020) Revisiting the Basis of Your China Strategy in the Post-Covid New Normal (7/1/2020) Trends in U.S. Multinational Enterprise Activity in China, 2000-2017 (7/1/2020) Ex-USPTO Head, Retired Judge Back China Pharma IP Reform (6/30/2020) How Data Protection Matters for Pharma Cos in Mainland China? - Ensuring Compliance and Mitigating Risk (6/30/2020) In Depth: Decoding China's First Civil Code (6/23/2020) Dealing with the Chinese Economy after COVID-19 (6/3/2020) Chinese Antitrust Authority Imposes Maximum Fine In Rare Abuse Of Collective Dominance Case (6/1/2020) Despite Stormy Days Ahead, Pockets of Hope and Opportunity Remain (6/1/2020) Challenges Posed to Chinese Biotechs in Post-Pandemic Era (5/28/2020) G1 Therapeutics and Simcere Enter Licens...  (8/3/2020) NHSA Solicits Feedbacks on the 2020 NRDL...  (8/3/2020) The CDE Solicits Comments on the Guidanc...  (8/3/2020) The CDE Solicits Comments on the Technic...  (8/3/2020) The CDE Solicits Comments on the Technic...  (8/3/2020) The CDE Solicits Comments on the Technic...  (8/3/2020) The CDE Solicits Comments on the Technic...  (8/3/2020) The CDE Solicits Comments on the Guideli...  (8/3/2020) NMPA Issues the Guidelines for Clinical ...  (8/3/2020) NMPA Solicits Comments on the Rules of P...  (8/3/2020) AstraZeneca's Q2 Growth Dragged Down by ...  (8/3/2020) Sesen Bio and Qilu Pharma Enter License ...  (8/3/2020) Pfizer's Topical Atopic Dermatitis Drug ...  (8/3/2020) Review of Chinese Drug Evaluation and Re...  (8/1/2020) NHSA Issues the Interim Measures for Adm...  (8/1/2020) Pfizer to Absorb Mylan, Creating Global Generic Powerhou... PhRMA Calls for Trade Deals That Force Countries to Pay ... IQVIA: Global Pharma to Grow Slower in the Next Five Yea... Pfizer and GSK Announce JV to Create a Global Consumer H... Top 25 Global Pharmaceutical Companies by Market Cap 201... Nicholas Hall Reports 4.5% Growth for the Chinese OTC Analgesic... IQVIA: Overall Chinese Pharma Market Growth Rebounded to 8.4% i... China Oncology Drugs Market - Growth Opportunities Created by C... Snapshot of Chinese Non-prescription Drug Market 2016-2019 IQVIA: Shanghai Drug Market Growth Up Substantially in 2019 G1 Therapeutics and Simcere Enter License Deal for Trilacicl... AstraZeneca's Q2 Growth Dragged Down by China Decline Sesen Bio and Qilu Pharma Enter License Deal for Vicineum in... Pfizer's Topical Atopic Dermatitis Drug Eucrisa Approved in ... Financial-related Company News in Brief The CDE Solicits Comments on the Guidance Principles on ... The CDE Solicits Comments on the Technical Guidelines fo... The CDE Solicits Comments on the Technical Guidelines fo... The CDE Solicits Comments on the Technical Guidelines fo... The CDE Solicits Comments on the Technical Guidelines on... NPC Solicits Comments on 2nd Draft of the Chinese Patent Law... Punitive Damages in China's New Civil Code SAMR Issues Notice to Strengthen Anti-Unfair Competition Enf... Beijing Plans to Criminalize Criticisms of Traditional Chine... NPC to Prioritize Legislation on Public Health in 2020 Fitch: No Near-Term Impact on Chinese API Makers as Phar... Indian Firms Challenged by API Price Hikes by Chinese Su... Snapshot of the Chinese API Sector India to Boost API Output as Alternative Source to China... India Lifts Export Restrictions on 24 APIs Terns Announces Completion and Positive Results from Pha... Gan & Lee Pharmaceuticals Initiates First-in Human P... Chi-Med's NDA for Savolitinib in Non-Small Cell Lung Can... BeiGene Announces Acceptance of NDA for Pamiparib in Ova... Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibit... NHSA Solicits Feedbacks on the 2020 NRDL Revision Work P... NHSA Issues the Interim Measures for Administration of B... NHC Issues Notice to Step Up Single Disease Group Qualit... APO Issues Bidding Documents for the Third Batch of VBP NHC Solicits Comments on the Rules for Clinical Applicat... Recent Executive Moves Recent Executive Moves Recent Executive Moves Senior Chinese Pharma Official Investigated for Serious Le... Recent Executive Movements USTR Satisfied with China's Implementatin of Phase 1 US-... U.S.-China ESRC Hearing: China's Evolving Healthcare Sys... AmCham Survey: Supply Chain Challenges for US Companies ... Upcoming Event: 2nd World Congress on Dermatology and Ae... Upcoming Event: XI International Exhibition of Equipment... Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector... WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...   WiCON Publishes the China Phar...   WiCON to Hold Pharma China Ann...   WiCON Publishes the China Phar...   WiCON Officially Publishes Chi...   WiCON Officially Publishes Chi...

© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links